A 'Null' Pattern of p16 Immunostaining in Endometrial Serous Carcinoma: An Under-recognized and Important Aberrant Staining Pattern
| Autor: | Les Henderson, Jin Xu, Xiangqiang Shao, Molly A. Accola, William M. Rehrauer, Vanessa L. Horner, Paul Weisman, Leah Frater-Rubsam, Daniel R. Matson |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Pathology
medicine.medical_specialty Serous carcinoma Context (language use) Biology medicine.disease_cause Article Pathology and Forensic Medicine CDKN2A medicine Biomarkers Tumor Humans Allele Cyclin-Dependent Kinase Inhibitor p16 Sequence Deletion Mutation Staining and Labeling Homozygote Obstetrics and Gynecology medicine.disease Cystadenocarcinoma Serous Endometrial Neoplasms Immunohistochemistry DNA mismatch repair Female Carcinoma Endometrioid Immunostaining |
| Zdroj: | Int J Gynecol Pathol |
| ISSN: | 1538-7151 |
| Popis: | The ability to distinguish endometrial serous carcinoma (SC) from high-grade endometrioid adenocarcinoma is of great importance given their differences in prognosis and management. In practice, this distinction typically relies upon the use of a focused immunohistochemical panel including p53, p16, and mismatch repair proteins. The expression of p16 is characteristically strong and diffuse in SCs, and weak and/or patchy in many high-grade endometrioid adenocarcinomas. Here, we report a subset of SCs that are entirely negative for p16 immunostaining, a pattern we refer to as "p16 null." This pattern was identified in 2 of 63 cases of SC diagnosed at our institution-1 with histologically classic features and 1 with ambiguous high-grade histologic features. These tumors otherwise showed a SC signature by immunohistochemical and demonstrated an SC pattern of genetic mutations. No mutation in the gene for p16, cyclin-dependent kinase inhibitor 2A (CDKN2A), was identified in either case. However, molecular correlates for the absent p16 expression were present, including homozygous deletion of CDKN2A in one case and hemizygous deletion of CDKN2A with promotor hypermethylation of the remaining allele in the other case. To our knowledge, this constitutes the first report conclusively demonstrating the existence of a small subset of SCs that are completely negative by p16 immunohistochemistry, and the molecular lesions responsible for this pattern. In the context of an otherwise clinically and histologically classic example of SC, we endorse this "null" p16 staining pattern as an alternative aberrant staining pattern that should not deter one from committing to this diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|